Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules
UC-0107/1810
Phase 2 small_molecule active
Quick answer
Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules for BRAF(V600) mutation-positive melanoma with brain metastasis (MBM) is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active